PharmaTher Holdings' affiliate Sairiyo Therapeutics is developing PD-001, an oral enteric-coated form of Cepharanthine, as a potential treatment for Hantavirus infections. Independent research shows Cepharanthine inhibits Hantavirus entry and infection in mice by over 90%, targeting early viral entry and membrane fusion stages. Sairiyo has approval to start a Phase 1 clinical trial to assess PD-001's safety and bioavailability in humans, although efficacy is not yet established. This development addresses the need for antiviral treatments against Hantavirus, which currently has no licensed therapies and poses significant health risks globally.
Cerebras Systems, an AI chip maker based in Sunnyvale, California, is set to go public on Nasdaq under the ticker CBRS on May 14, 2026, marking the first IPO from TSG Invest's Venture 50 Index. The company raised its IPO price range to $150-$160 per ...
Cerebras Systems, an AI chip maker known for its wafer-scale engine technology, is set to debut on Nasdaq under ticker CBRS, marking the first IPO from TSG Invest's Venture 50 Index. The company raised its IPO price range to $150-$160 per share due t...
Techstars has formed a strategic partnership with fintech platform Xendoo and accounting software Xero to offer startups a comprehensive financial operations solution. This collaboration aims to help early-stage companies maintain better financial vi...
Sapu Nano and Oncotelic have dosed the first patient in a Phase 1b clinical trial of Sapu003, an intravenous formulation of everolimus designed to treat advanced mTOR-sensitive solid tumors such as HR+/HER2- breast cancer and renal cell carcinoma. Th...
The Gabelli Utility Trust Board approved monthly cash distributions of $0.05 per share for July, August, and September 2026, maintaining its fixed monthly payout policy. The Fund's shares currently trade at a premium to net asset value, which the Boa...
